The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal Cancer (NCT06609434) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal Cancer
111 participantsStarted 2024-10
Plain-language summary
The goal of this clinical trial is to learn if radiofrequency ablation works to treat recurrent colorectal cancer liver metastases after surgery in adults. It will also learn about the safety of radiofrequency ablation. The main questions it aims to answer are:
Is radiofrequency ablation safe and effective in the treatment of recurrent colorectal cancer liver metastases? What medical problems do participants have when treating with radiofrequency ablation? Does radiofrequency ablation enable patients with recurrent colorectal cancer liver metastases to live longer? Researchers will compare systemic therapy combined with radiofrequency ablation to systemic therapy to see if radiofrequency ablation works to treat liver metastases better.
Participants will:
Receive systemic treatment for colorectal cancer liver metastases. Undergo (or not) radiofrequency ablation for colorectal cancer liver metastases.
Visit the hospital once every 3 months for checkups and tests.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with colorectal cancer whose primary lesions have been resected or can be controlled;
✓. Multiple confined lesions in the liver, the number of which can be defined;
✓. The liver contains at least 2 lesions suitable for radiofrequency ablation;
✓. The maximum diameter of the intrahepatic tumor is \<5 cm;
✓. The location of the hepatic lesion does not show obvious invasion with neighboring organs or large blood vessels;
✓. No extrahepatic metastases or stable extrahepatic metastases;
✓. Re-operative hepatic surgical resection is not indicated or refused;
✓. Ultrasound or ultrasonography can show intrahepatic lesions;
Exclusion criteria
✕. Suffering from, but not limited to, the following serious illnesses: congestive heart failure, myocardial infarction or cerebrovascular accident, or life-threatening cardiac arrhythmia within the last 6 months;
What they're measuring
1
liver progression-free survival
Timeframe: 2 years
Trial details
NCT IDNCT06609434
SponsorPeking University Cancer Hospital & Institute